Trevena Inc (TRVN)
OTHER OTC:TRVN
Top Page
No summary available
Positive Factors
Product Portfolio
OLINVYK's FDA approval for acute pain management provides a strong foundation for Trevena's product portfolio, supporting long-term revenue potential in the pain management sector.
Negative Factors
Financial Health
Trevena's negative equity and ongoing losses highlight severe financial instability, posing significant long-term risks to its operational sustainability and ability to invest in growth.
Read all positive and negative factors
Positive Factors
Negative Factors
Product Portfolio
OLINVYK's FDA approval for acute pain management provides a strong foundation for Trevena's product portfolio, supporting long-term revenue potential in the pain management sector.
Read all positive factors
Trevena (TRVN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$9.59K
Dividend YieldN/A
Average Volume (3M)1.10K
Price to Earnings (P/E)―
Beta (1Y)-0.26
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees23
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding863,788
10 Day Avg. Volume1,032
30 Day Avg. Volume1,103
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)-33.45
Price to Sales (P/S)81.95
P/FCF Ratio-7.74
Enterprise Value/Market Cap342.05
Enterprise Value/Revenue6.00
Enterprise Value/Gross Profit-2.26
Enterprise Value/Ebitda-0.13
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Trevena Business Overview & Revenue Model
Company Description
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G pro...
How the Company Makes Money
Trevena makes money primarily through the commercialization of its pharmaceutical products, particularly OLINVYK, which generates revenue from sales to hospitals and healthcare facilities. The company's revenue model is driven by product sales, li...
Trevena Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | TTM | Mar 2024 | Dec 2022 | Mar 2022 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 547.00K | 3.13M | -418.00K | 567.00K | 3.07M | 31.00K |
| Gross Profit | -1.45M | 1.46M | -3.44M | -387.00K | 2.89M | -77.00K |
| EBITDA | -26.20M | -34.95M | -52.03M | -51.08M | -28.66M | -25.61M |
| Net Income | -34.02M | -40.29M | -53.67M | -51.59M | -29.37M | -24.87M |
Balance Sheet | ||||||
| Total Assets | 19.19M | 40.60M | 48.68M | 80.12M | 127.74M | 46.99M |
| Cash, Cash Equivalents and Short-Term Investments | 13.46M | 32.98M | 38.32M | 66.92M | 109.40M | 35.80M |
| Total Debt | 37.56M | 36.24M | 19.77M | 7.10M | 7.80M | 13.46M |
| Total Liabilities | 42.50M | 48.26M | 33.08M | 15.49M | 23.67M | 16.92M |
| Stockholders Equity | -23.31M | -7.66M | 15.60M | 64.63M | 104.07M | 30.08M |
Cash Flow | ||||||
| Free Cash Flow | -27.11M | -33.08M | -51.51M | -50.21M | -21.42M | -23.67M |
| Operating Cash Flow | -27.09M | -33.03M | -51.48M | -50.20M | -21.39M | -23.67M |
| Investing Cash Flow | -21.00K | -41.00K | 18.00K | -16.00K | 3.47M | 25.58M |
| Financing Cash Flow | 5.70M | 26.31M | 23.50M | 7.73M | 95.02M | -2.50M |
Trevena Technical Analysis
Negative
0.01
Price Trends
0.01
Negative
0.01
Negative
0.27
Negative
Market Momentum
<0.01
Negative
44.41
Neutral
62.96
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TRVN, the sentiment is Negative. The current price of 0.01 is below the 20-day moving average (MA) of 0.01, below the 50-day MA of 0.01, and below the 200-day MA of 0.27, indicating a bearish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 44.41 is Neutral, neither overbought nor oversold. The STOCH value of 62.96 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TRVN.
Trevena Risk Analysis
Trevena disclosed 71 risk factors in its most recent earnings report. Trevena reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Trevena Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | $9.59K | ― | 145.94% | ― | ― | ― | |
49 Neutral | $2.08M | -0.24 | ― | ― | 178.82% | -4121.10% | |
44 Neutral | $5.19M | -0.28 | -203.36% | ― | ― | 90.53% | |
43 Neutral | $3.44M | -0.15 | -381.74% | ― | ― | 98.22% |
* Healthcare Sector Average
TRVN
Trevena
0.01
-1.19
-99.08%
SCNI
Scinai Immunotherapeutics
0.60
-1.93
-76.28%
GRI
GRI Bio
2.38
-39.90
-94.37%
DRMA
Dermata Therapeutics
1.29
-8.31
-86.56%
CERO
CERo Therapeutics Holdings
0.03
-14.27
-99.76%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―